Early Effectiveness Assessed for Fourth Dose of BNT162b2 Vaccine
Difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization, severe COVID-19
Difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization, severe COVID-19
Decrease larger in Hispanic, non-Hispanic Black versus non-Hispanic White population; decrease larger than in peer countries
The patient, a 67-year-old female, presented to the emergency department with altered mental status.
Expansion will allow millions of seniors to take care of medical problems while staying at home
In July 2017, Eagle had received a Complete Response Letter (CRL) from the FDA stating that an additional clinical trial would be needed prior to approval for the indication.
Preventive drugs, including antihypertensives and statins, frequently continued until final month of life
Risk increases associated with hormone therapy exposure over 10 years in women <60 years at initiation
Incremental cost-effectiveness ratio varied from $10,000 to $47,000 per QALY for RZV versus no vaccine
Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.